Dow Jones 10399.28 -22.77 8:39 am PST, September 23, 2005  NASDAQ 2109.12 -1.66 For info, visit access.smallcapnetwork.com S & P 500 1213.03 -1.59 Change your subscription status here Russell 2000 651.27 +0.11 VOLUME 05: ISSUE 72  Feature: Biocurex Steps Up to New Level BioCurex (BOCX.PK) steps up to new level. BioCurex, one of the Small Cap Digest's stalwart wins, was out with a very significant news announcement pre-open today (release below). For members of the SmallCap Digest, BOCX has been Mr. Toad's wild profit ride. Consider the trading history: First covered in October of '03 at $.17. Traded to $3.90 (2194% return) in April of '04. Halted for trading for three weeks by the SEC Traded down to $.50 in July of '04. Rebounded to $2.36 in May of '05. Currently camped in the $1 area. Today's news suggests another significant move could be in the cards as the company makes a move to step up to the next level. BOCX announced it has signed an Investment Banking Agreement with mid tier Atlanta based brokerage firm JP Turner. According to the release, JP Turner will assist BOCX with "market awareness". JP Turner has 120 offices nationwide. Over time, BOCX's revolutionary recaf cancer marker has the potential to generate significant profits through its licensing arrangement with $20 billion diagnostic testing behemoth Abbot Labs (NYSE: ABT). We anticipate this relationship will bring the company back to the Bulletin Board as a minimum, and bring a whole new audience to the stock. This new development could put the stock back on the upswing once again.     BioCurex Announces Investment Banking Agreement with J.P. Turner & Company, L.L.C. Friday September 23, 9:30 am ET RICHMOND, British Columbia, Sept. 23, 2005 (PRIMEZONE) -- BioCurex, Inc. (Other OTC:BOCX.PK - News), a biotechnology company, is pleased to announce it has formalized a relationship with J.P. Turner & Company, L.L.C. to assist the Company with market awareness and provide business advisory services. J.P. Turner, headquartered in Atlanta, is one of the nation's fastest growing full service brokerage firms with over 120 offices from coast-to-coast. J.P. Turner will provide BioCurex with introductions to other broker dealers, research analysts, and investment companies that J.P. Turner believes could be helpful to the Company and its shareholders. Among other services that J.P. Turner will provide to BioCurex, Turner will assist the Company with the identification and evaluation of potential acquisition candidates. The engagement is for 12 months Dr. Gerald Wittenberg, Director, stated: ``Their breadth of services and geographic reach will support numerous opportunities for the Company. We are looking forward to their assistance and introductions to the financial community as we progress in our licensing efforts for our RECAF based blood tests and future imaging and therapeutic applications. We recognize the value of J.P. Turner and their experience in the support of our initiatives. Expanding our exposure in the investment community with a well-known corporation such as J.P. Turner will be of considerable value as we move forward to achieve our corporate goals.'' About BioCurex BioCurex is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapeutics. The technology identifies a cancer marker known as RECAFtm, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To read more about the Company, please visit the News section on our web site (http://www.biocurex.com). Note: The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are ``forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.     Contact: BioCurex, Inc. Dr. R. Moro (604) 207 9150   Source: BioCurex, Inc.     We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 3525 Del Mar Heights Rd #334 San Diego, CA 92130 Subscribe Information is power and timely information is profitable. Become informed and profit from SmallCapDigest Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the SmallCapDigest Email Newsletter on a regular basis. To ensure newsletter delivery, you can add any additional email addresses you may have to the SmallCapDigest Member List. Receiving the SmallCapDigest Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the SmallCapDigest recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery. Subscribe Here Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the SmallCapDigest, simply follow the instructions located at the bottom of every SmallCapDigest Newsletter Edition. Unsubscribe Here D I S C L A I M E R: The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a licensed investment professional or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR Group, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Visit Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the company. Under SEC Rule 144, 570,000 shares of the 1 million newly issued restricted shares are now eligible for sale into the public market. TGR Group has submitted the approriate filings to sell the shares.  In addition, on March 22, 2005, TGR entered into an extended agreement with Biocurex for a fee of 25,000 newly issued restricted shares. Additionally, Some of the companies featured in the SmallCap Digest Newsletter pay an ESP (Electronic Service Provider) fee to an affiliated Technology Company for electronic delivery of this newsletter and other web related technology services. Fees range from $3,000 to $5,000 per month. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. From time to time TGR Group LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. The editor, members of the editor's family, and/or entities with  which the editor is affiliated aside from TGR Group LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain statements that appear forward as it relates to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.